347 related articles for article (PubMed ID: 23603816)
1. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.
Jameson KL; Mazur PK; Zehnder AM; Zhang J; Zarnegar B; Sage J; Khavari PA
Nat Med; 2013 May; 19(5):626-630. PubMed ID: 23603816
[TBL] [Abstract][Full Text] [Related]
2. The WW domain of the scaffolding protein IQGAP1 is neither necessary nor sufficient for binding to the MAPKs ERK1 and ERK2.
Bardwell AJ; Lagunes L; Zebarjedi R; Bardwell L
J Biol Chem; 2017 May; 292(21):8750-8761. PubMed ID: 28396345
[TBL] [Abstract][Full Text] [Related]
3. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
5. IQGAP1 is an oncogenic target in canine melanoma.
Lee BH; Neela PH; Kent MS; Zehnder AM
PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
[TBL] [Abstract][Full Text] [Related]
6. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
7. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
8. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
9. Copper is required for oncogenic BRAF signalling and tumorigenesis.
Brady DC; Crowe MS; Turski ML; Hobbs GA; Yao X; Chaikuad A; Knapp S; Xiao K; Campbell SL; Thiele DJ; Counter CM
Nature; 2014 May; 509(7501):492-6. PubMed ID: 24717435
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
11. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
Kaplan FM; Kugel CH; Dadpey N; Shao Y; Abel EV; Aplin AE
J Biol Chem; 2012 Dec; 287(50):41797-807. PubMed ID: 23076151
[TBL] [Abstract][Full Text] [Related]
12. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
13. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
14. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling.
Roy M; Li Z; Sacks DB
Mol Cell Biol; 2005 Sep; 25(18):7940-52. PubMed ID: 16135787
[TBL] [Abstract][Full Text] [Related]
15. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
[TBL] [Abstract][Full Text] [Related]
16. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
[TBL] [Abstract][Full Text] [Related]
17. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA
Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320
[TBL] [Abstract][Full Text] [Related]
18. That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
Sale MJ; Cook SJ
Br J Pharmacol; 2013 Aug; 169(8):1708-22. PubMed ID: 23647573
[TBL] [Abstract][Full Text] [Related]
19. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
20. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
